Skip to content

Tangshen decoction for the treatment of early stage diabetic nephropathy (stage III) prospective multicenter large sample cohort study

Tangshen decoction for the treatment of early stage diabetic nephropathy (stage III) prospective multicenter large sample cohort study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-16010113
Enrollment
Unknown
Registered
2016-12-08
Start date
2017-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic nephropathy stage ?

Interventions

Exposed group:Western conventional therapy + TCM Tangshen soup
Non-exposed group:Western conventional therapy

Sponsors

Beijing Shijitan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patient with a clear history of type 2 diabetes; 2. Meet the diagnostic criteria for type 2 DN,diabetic nephropathy stage III; 3. Aged 18 to 70 years; 4. In line with kidney yin deficiency syndrome or yang deficiency syndrome or yin and yang deficiency syndrome; 5. Subjects must be informed details of the trail and sign the informed consent; 6. Patients can provide detailed contact information, no short-term migration, willing to follow-up.

Exclusion criteria

Exclusion criteria: 1. Other primary diseases (chronic nephritis, hypertension, gout, lupus erythematosus, etc.) increased urinary albumin excretion rate; 2. Renal Vascular Hypertension; 3. Over the past six months there have been malignant hypertension, myocardial infarction, cerebrovascular accident, diabetic ketoacidosis and other critically illness; 4. With congestive heart failure?-? level; 5. The recent time(4 weeks) with severe infection; 6. Combined with heart, liver, brain, kidney and hematopoietic system and other serious primary disease, cancer, mental patients; 7. Pregnancy or preparation of pregnancy, breast-feeding women; 8. Known to the class of drug allergy and severe allergies; 9. Nearly 3 months to participate in other clinical trials of drug patients; 10. Those who do not fully understand this study, do not want to participate, or poor compliance,uncooperative (not with diet control, or do not follow the provisions of the efficacy of medication to determine the impact will be excude.

Design outcomes

Primary

MeasureTime frame
The incidence of end events;

Secondary

MeasureTime frame
blood glucose;glycosylated hemoglobin;ACR;SCr;blood pressure;BMI;Lipids;

Countries

China

Contacts

Public ContactXingzhong Feng

Beijing Shijitan Hospital, Capital Medical University

fengxz9797@sina.com+86 13381128811

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026